12,500,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by Foresite Capital Management VI LLC

Foresite Capital Management VI LLC bought a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,500,000 shares of the company's stock, valued at approximately $19,750,000. RAPT Therapeutics accounts for 8.8% of Foresite Capital Management VI LLC's investment portfolio, making the stock its 4th biggest position. Foresite Capital Management VI LLC owned about 35.76% of RAPT Therapeutics at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Picton Mahoney Asset Management boosted its holdings in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after buying an additional 14,697 shares during the period. Los Angeles Capital Management LLC lifted its position in shares of RAPT Therapeutics by 9.2% during the fourth quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock worth $348,000 after acquiring an additional 18,558 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after acquiring an additional 25,130 shares during the period. Barclays PLC grew its position in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company's stock valued at $79,000 after purchasing an additional 29,195 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of RAPT Therapeutics by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock valued at $1,133,000 after purchasing an additional 33,758 shares in the last quarter. Hedge funds and other institutional investors own 99.09% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $4.00.

RAPT Therapeutics Price Performance

NASDAQ RAPT traded up $0.05 during trading on Friday, reaching $0.97. The company's stock had a trading volume of 904,905 shares, compared to its average volume of 1,277,851. The stock has a market capitalization of $127.62 million, a PE ratio of -0.35 and a beta of -0.29. The firm has a fifty day moving average of $1.06 and a 200 day moving average of $1.29. RAPT Therapeutics, Inc. has a one year low of $0.75 and a one year high of $8.58.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.69). Research analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.